Ubs Group Ag Argenx Se Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Argenx Se stock. As of the latest transaction made, Ubs Group Ag holds 53,793 shares of ARGX stock, worth $48.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

53,793

Previous 68,276 21.21%

Holding current value

$48.8 Million

Previous $37.6 Million 5.42%

% of portfolio

0.01%

Previous 0.01%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$538.64 - $768.0 $7.8 Million - $11.1 Million	-14,483 Reduced 21.21%	53,793 $39.7 Million
Q2 2025 Aug 14, 2025	SELL	$532.27 - $656.65 $18 Million - $22.2 Million	-33,863 Reduced 33.15%	68,276 $37.6 Million
Q1 2025 May 13, 2025	BUY	$571.0 - $671.75 $47 Million - $55.2 Million	82,239 Added 413.26%	102,139 $60.5 Million
Q4 2024 Feb 14, 2025	BUY	$520.52 - $638.33 $9.36 Million - $11.5 Million	17,983 Added 938.08%	19,900 $12.2 Million
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $126,358 - $160,602	-291 Reduced 13.18%	1,917 $1.04 Million

Q2 2024 Aug 13, 2024	SELL	$356.01 - $451.55 $309,728 - $392,848	-870 Reduced 28.27%	2,208 $949,000
Q1 2024 May 13, 2024	BUY	$356.95 - $413.29 $507,225 - $587,285	1,421 Added 85.76%	3,078 $1.21 Million
Q4 2023 Feb 09, 2024	SELL	$338.91 - $506.01 $19,317 - $28,842	-57 Reduced 3.33%	1,657 $630,000
Q3 2023 Nov 09, 2023	SELL	$369.35 - $548.43 $113,390 - $168,368	-307 Reduced 15.19%	1,714 $842,000
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $175,748 - $206,219	488 Added 31.83%	2,021 $787,000
Q1 2023 May 12, 2023	SELL	$334.23 - $403.65 $785,440 - $948,577	-2,350 Reduced 60.52%	1,533 $571,000
Q4 2022 Feb 08, 2023	BUY	$342.17 - $402.31 $678,865 - $798,183	1,984 Added 104.48%	3,883 $1.47 Million
Q3 2022 Nov 10, 2022	SELL	$343.2 - $395.75 $1.18 Million - $1.36 Million	-3,430 Reduced 64.36%	1,899 $671,000
Q2 2022 Aug 10, 2022	BUY	$269.58 - $378.88 $38,010 - $53,422	141 Added 2.72%	5,329 $2.02 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $748,591 - $1.03 Million	-2,942 Reduced 36.19%	5,188 $1.64 Million
Q4 2021 Feb 14, 2022	SELL	$272.01 - $353.03 $1.19 Million - $1.55 Million	-4,381 Reduced 35.02%	8,130 $2.85 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $1.03 Million - $1.23 Million	3,501 Added 38.86%	12,511 $3.78 Million
Q2 2021 Aug 13, 2021	BUY	$257.11 - $319.92 $920,968 - $1.15 Million	3,582 Added 65.99%	9,010 $2.71 Million
Q1 2021 May 12, 2021	BUY	$268.3 - $380.31 $888,341 - $1.26 Million	3,311 Added 156.4%	5,428 $1.5 Million
Q4 2020 Feb 11, 2021	BUY	$248.13 - $308.36 $21,835 - $27,135	88 Added 4.34%	2,117 $623,000
Q3 2020 Nov 12, 2020	SELL	$215.51 - $272.51 $55,817 - $70,580	-259 Reduced 11.32%	2,029 $533,000
Q2 2020 Jul 31, 2020	SELL	$127.44 - $232.72 $53,397 - $97,509	-419 Reduced 15.48%	2,288 $515,000
Q1 2020 May 01, 2020	BUY	$108.83 - $165.23 $121,889 - $185,057	1,120 Added 70.57%	2,707 $357,000
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $131,105 - $201,978	-1,230 Reduced 43.66%	1,587 $255,000
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $1.05 Million - $1.39 Million	-9,225 Reduced 76.61%	2,817 $321,000
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $1.01 Million - $1.25 Million	8,821 Added 273.86%	12,042 $1.71 Million
Q1 2019 May 14, 2019	BUY	$98.85 - $134.59 $10,774 - $14,670	109 Added 3.5%	3,221 $402,000
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $7,593 - $13,068	-119 Reduced 3.68%	3,112 $299,000
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $180,143 - $230,559	2,386 Added 282.37%	3,231 $245,000
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $10,552 - $14,122	141 Added 20.03%	845 $70,000
Q1 2018 May 15, 2018	SELL	$56.95 - $85.19 $40,092 - $59,973	-704 Reduced 50.0%	704 $57,000
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $31,778 - $89,492	1,408	1,408 $89,000

Others Institutions Holding ARGX

# of Institutions

525

Shares Held

26M

Call Options Held

589K

Put Options Held

320K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account